MARKET NEWS

 

Newron Initiates First Potentially Pivotal Study With Evenamide in Patients With Schizophrenia
AIM ImmunoTech Submits Pre-IND Application to the FDA for Phase 2 Clinical Study of Ampligen as a Potential Infusion Therapy for Post-COVID-19 Cognitive Dysfunction
Soleno Therapeutics Announces Positive Data Showing Continued Significant Improvements in Symptoms of PWS Following 1 Year Treatment With DCCR
Celsion Reports T-cell & B-cell Response From In Vivo Studies With its PLACCINE DNA Vaccine Platform
TCR² Therapeutics Receives FDA Orphan Drug Designation for Gavo-cel for the Treatment of Cholangiocarcinoma
Adamis Pharmaceuticals Doses First Patients in Phase 2/3 Clinical Trial for Tempol in the Treatment of COVID-19

  FEATURED EDITORIAL


  COMPANY PROFILE

The Health business of Lubrizol Life Science (LLS Health), in partnership with customers, advances solutions inspiring a healthier life. We specialize in helping clients from idea to execution by offering innovative polymers and excipients, as well as best-in-class contract development and manufacturing services. Our long history of polymer expertise and continued investment in research and manufacturing means we offer you and your customers a smooth and streamlined approach to innovative healthcare solutions. Click here for more.

  EXCLUSIVE ONLINE CONTENT

MacroGenics Announces Final Overall Survival Results From SOPHIA Study of MARGENZA in Patients with HER2-Positive Metastatic Breast Cancer

MacroGenics Announces Final Overall Survival Results From SOPHIA Study of MARGENZA in Patients with HER2-Positive Metastatic Breast Cancer

MacroGenics, Inc. recently announced the final overall survival (OS) results of the SOPHIA Phase 3 study in adult patients with metastatic HER2-positive breast cancer…..

Medrio, Inc. & PHASTAR Unite to Offer Data Visualization for Clinical Trials

Medrio, Inc. & PHASTAR Unite to Offer Data Visualization for Clinical Trials

Medrio and PHASTAR recently announced they have partnered to leverage metadata surrounding electronic patient-reported outcomes (ePRO) for advanced data visualization, providing insight into….

Nature Medicine Publishes Positive Phase 3 Anakinra Study Results in Patients With COVID-19 Pneumonia

Nature Medicine Publishes Positive Phase 3 Anakinra Study Results in Patients With COVID-19 Pneumonia

Swedish Orphan Biovitrum AB (Sobi) and the Hellenic Institute for the Study of Sepsis recently announced that Nature Medicine has published positive results from the investigator-sponsored Phase 3….

Impel NeuroPharma Announces US FDA Approval of TRUDHESA Nasal Spray for the Acute Treatment of Migraine

Impel NeuroPharma Announces US FDA Approval of TRUDHESA Nasal Spray for the Acute Treatment of Migraine

Impel NeuroPharma, Inc. recently announced the US FDA approved TRUDHESA (dihydroergotamine mesylate) nasal spray (0.725 mg per spray) for the acute treatment of migraine with or without aura….

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

September 29 – Gene Therapy
October 6 – API Synthesis